Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The FDA Weighs In | Main | No Drug Is An Island »

December 19, 2004

Boarding Up the Windows

Email This Entry

Posted by Derek

In almost every story about Pfizer's disastrous Friday, you'll find a sentence with this phrase in it: ". . .the company says it has no plans to recall Celebrex. . ." But this statement, taken literally, is surely untrue.

Pfizer definitely does not want to recall Celebrex. They've been in the Red Queen's Race of the pharmaceutical world for a few years now - they have to run as fast as they can to stay in the same place. To me, none of the estimates of how many billion-dollar launches they need have ever seemed attainable, and their method of just going out and buying the biggest drugs they could find has never made sense. Losing Celebrex would put an ugly dent in their strategic plan, even in the eyes of people who believe in it.

Neither do I have enough data to hand (nor, for this kind of decision, enough expertise) to say whether Celebrex even should be recalled. But whether it should or not, I'd say the odds are better than even that it will be. Such is the climate.

And you can be sure that Pfizer has thought about it, about what they'd have to do and how they would do it. You can be sure that someone over in Groton or New London has that job, and you can be equally sure that they didn't get home very much over the weekend. There's a lengthy PowerPoint presentation ready by now that no one wants to deliver. Don't take Pfizer's word for it - there are plans, because there have to be.

Comments (1) + TrackBacks (0) | Category: Cardiovascular Disease


COMMENTS

1. Daniel Newby on December 21, 2004 2:07 AM writes...

BusinessWeek article: Pfizer and Merck: Different Strokes

Tasteless title? We report—you decide.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .